NASDAQ:CBAY CymaBay Therapeutics (CBAY) Earnings Date, Estimates & Call Transcripts $8.75 +0.20 (+2.34%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$8.53▼$8.8450-Day Range$8.47▼$10.8352-Week Range$1.81▼$11.22Volume558,308 shsAverage Volume1.36 million shsMarket Capitalization$853.21 millionP/E RatioN/ADividend YieldN/APrice Target$14.57 EarningsProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Earnings Summary Upcoming Earnings DateAug. 10EstimatedActual EPS (Mar. 16) -$0.30 Consensus EPS (Mar. 16) -$0.30 Last Year's Q1 EPS (3/17/2022) -$0.34Read Call TranscriptListen to CallSkip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueCBAY Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CBAY Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.CymaBay Therapeutics Analyst ForecastsQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20233($0.32)$0.06($0.18)Q2 20234($0.32)$0.04($0.22)Q3 20234($0.33)($0.28)($0.31)Q4 20234($0.45)$0.00($0.25)FY 202315($1.42)($0.18)($0.95)Q1 20241($0.34)($0.34)($0.34)Q2 20241($0.41)($0.41)($0.41)Q3 20241($0.47)($0.47)($0.47)Q4 20241($0.49)($0.49)($0.49)FY 20244($1.71)($1.71)($1.71) Get CymaBay Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for CBAY and its competitors with MarketBeat's FREE daily newsletter. CBAY Earnings Date and InformationCymaBay Therapeutics last issued its earnings data on March 16th, 2023. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.30). CymaBay Therapeutics has generated ($1.18) earnings per share over the last year (($1.18) diluted earnings per share). Earnings for CymaBay Therapeutics are expected to remain at ($1.01) per share in the coming year. CymaBay Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 10th, 2023 based off prior year's report dates.Read More CymaBay Therapeutics Earnings History by Quarter Export to ExcelDateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/10/2023(Estimated) 3/16/2023Q4 2022($0.30)($0.30)($0.30) 11/14/2022Q3 2022($0.30)($0.28)+$0.02($0.28)8/11/2022Q2 2022($0.30)($0.31)($0.01)($0.31) 5/12/2022Q1 2022($0.31)($0.32)($0.01)($0.32) 3/17/2022Q4 2021($0.36)($0.34)+$0.02($0.34) 11/10/20219/30/2021($0.26)($0.33)($0.07)($0.33) 8/12/20216/30/2021($0.27)($0.34)($0.07)($0.34) 5/13/20213/31/2021($0.24)($0.25)($0.01)($0.25) 3/24/202112/31/2020($0.20)($0.23)($0.03)($0.23) 11/5/20209/30/2020($0.17)($0.17)($0.17) 8/10/20206/30/2020($0.23)($0.16)+$0.07($0.16) 5/11/20203/31/2020($0.31)($0.19)+$0.12($0.19) 3/12/2020Q4 2019($0.39)($0.43)($0.04)($0.28) 11/5/2019Q3($0.37)($0.38)($0.01)($0.38) 8/7/2019Q2 2019($0.37)($0.35)+$0.02($0.35)5/8/20193/31/2019($0.34)($0.37)($0.03)($0.37) 2/28/2019Q4 2018($0.36)($0.32)+$0.04($0.32)11/6/20189/30/2018($0.30)($0.34)($0.04)($0.34)8/10/2018Q2 2018($0.25)($0.2910)($0.0410)($0.30)5/9/2018Q1 2018($0.14)($0.32)($0.18)($0.32)$5.00 million3/15/2018Q4 2017($0.17)($0.11)+$0.06($0.11)$1.25 million$5.20 million 11/8/2017Q3 2017($0.19)($0.21)($0.02)($0.21)$9.50 million8/10/2017Q2 2017($0.25)($0.31)($0.06)($0.31)5/11/2017Q1 2017($0.2670)($0.20)+$0.0670($0.20)$4.79 million3/23/2017Q4 2016($0.28)($0.30)($0.02)($0.30)11/9/2016Q3 2016($0.31)($0.25)+$0.06($0.25) 8/9/2016Q2($0.32)($0.30)+$0.02($0.30)5/11/2016Q1($0.28)($0.29)($0.01)($0.29) 3/29/2016Q4($0.35)($0.26)+$0.09($0.26) 11/12/2015Q315($0.33)($0.27)+$0.06($0.27) 8/10/2015Q215($0.42)($0.09)+$0.33($0.09) 5/7/2015Q1 2015($0.43)($0.44)($0.01)($0.44)3/18/2015Q414($0.46)($0.87)($0.41)($0.87)11/12/2014Q314($0.48)($0.44)+$0.04($0.44)CymaBay Therapeutics Earnings - Frequently Asked Questions When is CymaBay Therapeutics's earnings date? CymaBay Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 10th, 2023 based off last year's report dates. Learn more on CBAY's earnings history. Did CymaBay Therapeutics beat their earnings estimates last quarter? In the previous quarter, CymaBay Therapeutics (NASDAQ:CBAY) reported ($0.30) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.30). Learn more on analysts' earnings estimate vs. CBAY's actual earnings. How can I listen to CymaBay Therapeutics's earnings conference call? The conference call for CymaBay Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read CymaBay Therapeutics's conference call transcript? The conference call transcript for CymaBay Therapeutics's latest earnings report can be read online. Read Transcript How much profit does CymaBay Therapeutics generate each year? CymaBay Therapeutics (NASDAQ:CBAY) has a recorded net income of -$106 million. CBAY has generated -$1.18 earnings per share over the last four quarters. What is CymaBay Therapeutics's EPS forecast for next year? CymaBay Therapeutics's earnings are expected to stay at ($1.01) per share in the next year. More Earnings Resources from MarketBeat Related Companies: RYTM Earnings INVA Earnings BHVN Earnings QURE Earnings ARDX Earnings DAWN Earnings KNSA Earnings MRUS Earnings ME Earnings MRSN Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Costco's Earnings Call Reassure Economists, Recession Cancelled Best Buy's Comeback Is Still At Play, Earnings Call For Patience 2 Energy Mid-Caps Expected To Post Monster Earnings GrowthPetCo Management Getting it Right? Earnings Beat Says YesAutoZone Reports Earnings Beat, Shares Fall, Outlook PositiveCan Ryanair Stock Fly Above Resistance Levels, What Earnings ShowAnalyst Flags Concerns About P&G Growth Despite Earnings Beat This page (NASDAQ:CBAY) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CymaBay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.